Abcam, ab250777, Anti-Phospholipase C beta 1/PLCB1+ Phospholipase C beta 3/PLCB3 antibody [EPR18714]-BSA & Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Phospholipase C beta 1/PLCB1 antibody. Carrier free. Suitable for IP, WB, IHC-P and reacts with Mouse, Rat, Human, Recombinant fragment - Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR18714,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:IHC-P, IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250777 is the carrier-free version of
ab184743
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Phospholipase C beta 1 (PLCB1) and Phospholipase C beta 3 (PLCB3) are enzymes known for their role in phosphoinositide hydrolysis. These proteins catalyze the conversion of phosphatidylinositol 45-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG) important secondary messengers in cellular signaling. PLCB1 has a molecular mass of approximately 138 kDa while PLCB3 is approximately 150 kDa. Both PLCB1 and PLCB3 are expressed widely in the central nervous system and various peripheral tissues indicating their involvement in diverse physiological processes.
Biological function summary
PLCB1 and PLCB3 influence intracellular calcium levels and protein kinase C activity by generating IP3 and DAG respectively. These proteins do not operate in isolation but interact with other signaling molecules forming parts of larger signaling complexes. They modulate neuronal signaling pathways which impact processes such as neurotransmitter release. This involvement highlights their importance in maintaining normal cellular communication and function.
Pathways
PLCB1 and PLCB3 play significant roles in the G-protein coupled receptor (GPCR) signaling pathway. They function downstream of the receptor activation being activated by Gq proteins leading to the production of secondary messengers. The enzymes also participate in the phosphatidylinositol signaling pathway particularly influencing calcium signaling. The interaction of PLCB1 and PLCB3 with Gq proteins highlights their integration into diverse signaling networks that communicate extracellular signals to elicit intracellular responses.
Dysfunction of PLCB1 and PLCB3 links to various neurological diseases and certain forms of cancer. Abnormalities in PLCB1 expression associate with epilepsy indicating its role in neural excitability and signaling balance. Altered PLCB3 activity contributes to the development of breast cancer where its interaction with proteins like protein kinase C influences proliferative signaling pathways. These connections highlight the potential of targeting PLCB1 and PLCB3 to develop therapeutic strategies for related conditions.